Delving into the Latest Updates on Xechem International, Inc. with Synapse

Overview

Tags

Congenital Disorders

Hemic and Lymphatic Diseases

Other Diseases

Herbal medicine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Herbal medicine	1

Top 5 Target	Count

Hemoglobins	1

Calpain activation has been implicated in the disease pathology of Duchenne muscular dystrophy. Inhibition of calpain has been proposed as a promising therapeutic target, which could lessen the protein degradation and prevent progressive fibrosis. At the same time, there are conflicting reports as to whether elevation of calpastatin, an endogenous calpain inhibitor, alters pathology. We compared the effects of pharmacological calpain inhibition in the mdx mouse using leupeptin and a proprietary compound (C101) that linked the inhibitory portion of leupeptin to carnitine (to increase uptake into muscle). Administration of C101 for 4 wk did not improve muscle histology, function, or serum creatine kinase levels in mdx mice. Mdx mice injected daily with leupeptin (36 mg/kg) for 6 mo also failed to show improved muscle function, histology, or creatine kinase levels. Biochemical analysis revealed that leupeptin administration caused an increase in m-calpain autolysis and proteasome activity, yet calpastatin levels were similar between treated and untreated mdx mice. These data demonstrate that pharmacological inhibition of calpain is not a promising intervention for the treatment of Duchenne muscular dystrophy due to the ability of skeletal muscle to counter calpain inhibitors by increasing multiple degradative pathways.

100 Deals associated with Xechem International, Inc.

Login to view more data

100 Translational Medicine associated with Xechem International, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Niprisan ( Hemoglobins )	Anemia, Sickle Cell More	Approved
C-203	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating More	Discontinued
Neurodur ( Calpain1/2 )	Multiple Sclerosis More	Discontinued
C-102 ( CAPN1 )	Myasthenia Gravis More	Discontinued